A burgeoning caseload and the retirement of key specialist judges might adversely affect the performance of the US district court for the District of Delaware in pharma patent litigation, according to Owen Byrd, general counsel and chief evangelist of Lex Machina, which has just produced its 2018 Hatch-Waxman ANDA Litigation Report.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Straight talk on key IP issues, IAM aims to provide executive managers with the business perspective that often gets lost in technical jargon and legal details.

Gene Potkay
Senior vice president of intellectual property
The Nielsen Company

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?